Opportunity Alert – AC-160105-085 – ROCHE-02
Date Sourced: March 9, 2016
Category: Customer Opportunity
Status: Qualifying
Potential (High-Moderate-Low): Moderate
Add to SFA (Y/N): TBD
Client Action Required (Y/N): No
Opportunity:
Roche is the worlds largest bio-pharmaceutical company and is headquartered
in Basel, Switzerland. The company takes a targeted, personalized treatment
approach to drug development. As a global leader in cancer medicines, Roche
has pipeline drugs aimed at breast, skin, colon, ovarian, lung and numerous
other cancers.
Website: www.roche.com/
Summary of Activities/Tasks:
1. March 9, 2016 – Contacted Daniel Umbricht, Director Neuroscience,
Ophthalmology, Rare Diseases, Roche Pharma R&D. Invited to the CleverCap
Med Adherence CxO Briefing on March 22, 2016. No response.
2. March 22, 2016 – Met with Komathi Stern at CTC conference. Komathi is
a Strategic Innovation Leader, Roche/Genentech; and involved with piloting
their virtual clinical trial initiative.
3. March 30, 2016 – Followed up with Daniel after speaking with Komathi.
Daniel responded on March 31st. Coordinating conference call.
4. April 1, 2016 – Scheduled and confirmed conference call on April 8th
at 9 AM with Daniel to discuss CleverCap.
Forward Statements and Guidance:
Roche is clearly committed as an organization to pursing innovative, virtual
clinical trials. CleverCap is expected to be well-received by leadership and
there will be several management-level champions for us to contact. Provided
we can identify a suitable, upcoming and oral-based trail, we expect to close
a deal with Roche. Additional updates to follow after the April 9th meeting.
End.
Return to Listing
COMMENT FORM.
Comments
Facilitator
Followed-up with Daniel. Waiting for feedback from Judy Dunn, Roche Head of Operations, Early Development, Operations Group.
Facilitator
Friday, April 8, 2016 – Conference call with Daniel Umbricht from Roche HQ, Switzerland. Roche is focusing more on Alzheimer, Autism and Schizophrenia studies where med adherence can be a major challenge. Sees a strong need for CleverCap within the neuroscience clinical study area.
Daniel has 2 immediate studies, however, one is too far along in design and the other will dispense a mix of compound granules (not capsule or tablets). CleverCap would need to be augmented to weight and/or measure the quantify dispensed. This is not typical of Roche studies and Daniel is confident that he will find application for CleverCap in his future studies.
In the meantime, the Roche operations group is in UK, Wellington and oversees all trial design. Daniel is forwarding the CleverCap deck and advocating its use. Ron will follow-up in 2-3 weeks to identify interest within other Roche studies. Med adherence is a constant topic heard from Roche executive management.